ArticleJournal of the Endocrine Society2025
Adherence and Growth Outcomes in a Large Cohort of Children Treated With Recombinant GH Using a Connected Auto-injector.
Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Influence of long-acting growth hormone analogs on other hypothalamic-pituitary axes: a real-world study.Journal of endocrinological investigation · 2026Article
- Can long-acting growth hormone improve adherence in pediatric growth hormone deficiency?Endocrine · 2026Review
- Yushida: an IoT-based smart injection system for long-term management of chronic diseases.Frontiers in digital health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Adherence to recombinant GH treatment is crucial to achieve optimal adult height in children with growth disorders. Information on factors responsible for differences in adherence and growth in different countries is limited. Aim: To evaluate adherence and catch-up growth in children receiving GH using Easypod® auto-injectors. Methods: Retrospective cohort analysis of adherence and height, from 481 children (55% boys) in 19 centers in France, from the Growzen® Connect database, from mid-2018 to end-2023. Adherence was classified as high (≥85% of injections) or medium/low (<85%). Gain in height SD score (HSDS) was evaluated after 1 and 2 years of GH treatment. Results: High adherence was maintained throughout for 85% of patients. Among children who started young (mean age 6.3 years), 91% had high adherence over the first 2 years, significantly more than the 83% among those starting older (13.1 years) ( Conclusion: Children using Easypod exhibit high adherence, which aids clinical decision-making and patient engagement. Adherence and catch-up growth decrease with age. Indication for GH treatment had little impact, but overall catch-up growth was significantly greater with high adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.